Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels

Breast Cancer Research and Treatment

Volumn 136, Issue 2, 2012, Pages 573-579

  Diorio, Caroline ^a,b   Lemieux, Julie ^a   Provencher, Louise ^a,b   Hogue, Jean Charles ^a   Vachon, Eric ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Aromatase inhibitor; Breast cancer; Estradiol; Obesity

Indexed keywords

ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; ESTRADIOL; EXEMESTANE; LETROZOLE;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; BREAST CANCER; CANCER RECURRENCE; DISEASE ASSOCIATION; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AROMATASE INHIBITORS; BODY MASS INDEX; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; OBESITY; QUALITY OF LIFE;

EID: 84868194269     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2278-z     Document Type: Article

References (45)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212-236. doi:10.3322/caac.20121
2. Anderson WF, Katki HA, Rosenberg PS (2011) Incidence of breast cancer in the United States: Current and future trends. J Natl Cancer Inst 103(18):1397-1402. doi:10.1093/jnci/djr257
3. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R (2011) NCCN clinical practice guidelines in oncology: Breast cancer, V.2.2011 edn. National Comprehensive Cancer Network (NCCN), Fort Washington
4. MillerWR(2006) Aromatase and the breast: Regulation and clinical aspects. Maturitas 54(4):335-341. doi:10.1016/j.maturitas.2006. 04.020
5. International Association for the Study of Obesity (2012) http:// www.iaso.org/. Accessed 28 June 2012
6. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569-578. doi:10.1016/S0140-6736(08) 60269-X
7. Montazeri A, Sadighi J, Farzadi F, Maftoon F, Vahdaninia M, Ansari M, Sajadian A, Ebrahimi M, Haghighat S, Harirchi I (2008) Weight, height, body mass index and risk of breast cancer in postmenopausal women: A case-control study. BMC Cancer 8:278. doi:10.1186/1471-2407-8-278
8. Brown KA, Simpson ER (2010) Obesity and breast cancer: Progress to understanding the relationship. Cancer Res 70(1):4-7. doi:10.1158/0008-5472.CAN- 09-2257
9. Enger SM, Greif JM, Polikoff J, Press M (2004) Body weight correlates with mortality in early-stage breast cancer. Arch Surg 139(9): 954-958. doi:10.1001/archsurg.139.9.954 (discussion 958-960)
10. Maccio A, Madeddu C, Mantovani G (2009) Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: New therapeutic perspectives. Obes Rev 10(6):660-670. doi:10.1111/j.1467-789X.2009.00592.x
11. Geisler J, Haynes B, Ekse D, Dowsett M, Lonning PE (2007) Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. J Steroid Biochem Mol Biol 104(1-2):27-34. doi:10.1016/j.jsbmb.2006. 09.040
12. Miller WR, Anderson TJ, Evans DB, Krause A, Hampton G, Dixon JM (2003) An integrated view of aromatase and its inhibition. J Steroid Biochem Mol Biol 86(3-5):413-421
13. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. J Clin Oncol 28(21):3411-3415. doi:10.1200/JCO. 2009.27.2021
14. Ware JE, Jr. SF-36-Health Survey Update. http://www.sf-36.org/tools/sf36. shtml. Accessed 27 Aug 2012
15. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473-48
16. Hilditch JR, Lewis J, Peter A, van Maris B, Ross A, Franssen E, Guyatt GH, Norton PG, Dunn E (1996) A menopause-specific quality of life questionnaire: Development and psychometric properties. Maturitas 24(3):161-175
17. Radtke JV, Terhorst L, Cohen SM (2011) The menopause-specific quality of Life Questionnaire: Psychometric evaluation among breast cancer survivors. Menopause 18(3):289-295. doi:10.1097/gme.0b013e3181ef975a
18. Park MH, Falconer C, Viner RM, Kinra S (2012) The impact of childhood obesity on morbidity and mortality in adulthood: A systematic review. Obes Rev. doi:10.1111/j.1467-789X.2012. 01015.x
19. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, Lopez AM, Manson J, Margolis KL, Muti PC, Stefanick ML, McTiernan A (2002) Obesity, body size, and risk of postmenopausal breast cancer: The women's health initiative (United States). Cancer Causes Control 13(8):741-751
20. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D (2007) Cancer incidence and mortality in relation to body mass index in the million women study: Cohort study. BMJ 335(7630):1134. doi:10.1136/bmj.39367.495995.AE
21. Loi S, Milne RL, Friedlander ML, McCredie MR, Giles GG, Hopper JL, Phillips KA (2005) Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14(7):1686-1691. doi:10.1158/1055-9965.EPI-05-0042
22. Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: Systematic review and meta-analysis. Breast Cancer Res Treat 123(3):627-635. doi: 10.1007/s10549-010-0990-0
23. Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95(19):1467-1476
24. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625-1638. doi:10.1056/NEJMoa021423
25. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA (2005) Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 14(8):2009-2014. doi:10.1158/1055-9965.EPI-05-0106
26. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B (2008) Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 111(2):329-342. doi:10.1007/s10549-007-9785-3
27. Petrelli JM, Calle EE, Rodriguez C, Thun MJ (2002) Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control 13(4): 325-332
28. Ewertz M, Jensen MB, Gunnarsdottir KA, Hojris I, Jakobsen EH, Nielsen D, Stenbygaard LE, Tange UB, Cold S (2011) Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 29(1):25-31. doi:10.1200/JCO.2010.29. 7614
29. Lorincz AM, Sukumar S (2006) Molecular links between obesity and breast cancer. Endocr Relat Cancer 13(2):279-292. doi:10.1677/erc.1.00729
30. Hursting SD, Berger NA (2010) Energy balance, host-related factors, and cancer progression. J Clin Oncol 28(26):4058-4065. doi:10.1200/JCO.2010.27.9935
31. Formica V, Tesauro M, Cardillo C, Roselli M (2012) Insulinemia and the risk of breast cancer and its relapse. Diabetes Obes Metab. doi:10.1111/j.1463- 1326.2012.01614.x
32. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R, Goldfine ID, Belfiore A (1992) Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52(14): 3924-3930
33. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, Kopelovich L, Hudis CA, Dannenberg AJ (2012) Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2(4):356-365. doi:10.1158/2159-8290.CD-11-0241
34. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neugut AI (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291(20): 2433-2440. doi:10.1001/jama.291.20.2433
35. Rose DP, Gilhooly EM, Nixon DW (2002) Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin (review). Int J Oncol 21(6):1285-1292
36. Revillion F, Charlier M, Lhotellier V, Hornez L, Giard S, Baranzelli MC, Djiane J, Peyrat JP (2006) Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers. Clin Cancer Res 12(7 Pt 1):2088-2094. doi:10.1158/1078-0432.CCR-05-1904
37. Bulun SE, Chen D, Moy I, Brooks DC, Zhao H (2011) Aromatase, breast cancer and obesity: A complex interaction. Trends Endocrinol Metab 23(2):83-89. doi:10.1016/j.tem.2011.10.003
38. Schmid P, Possinger K, Bohm R, Chaudri H, Verbeek A, Grosse Y, Luftner D, Petrides PE, Sezer O, Wischnewsky M (2000) Body mass index as predictive parameter for response and time to progression (TTP) in advanced breast cancer patients treated with letrozole or megestrol acetate. Proc Am Soc Clin Oncol 19:103a (abstr 398)
39. Pfeiler G, Konigsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Postlberger S, Steger GG, Seifert M, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial. J Clin Oncol 29(19):2653-2659. doi:10.1200/JCO.2010.33.2585
40. Michaud L, Buzdar A, Rubin S, Steinberg M, Yin H, Aaronson L, Nabholtz J (2002) The efficacy of anastrozole is not dependent upon body mass index (BMI) in postmenopausal women with advanced breast cancer (BC). Proc Am Soc Clin Oncol 21:55a (abstr 219)
41. Pfeiler G, Stöger H, Singer C, Seifert M, Jakesz R, Dubsky P, Samonigg H, Greil R, Menzel C, Heck D, Gnant M (2010) Impact of body mass index (BMI) on the efficacy of endocrine therapy in postmenopausal breast cancer patients-an analysis of the ABCSG 6 and 6a Trial. San Antonio Breast Cancer Conf abstract PD-09-05
42. Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M (2012) Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 30(24):2977-2980. doi:10.1200/JCO.2012. 42.0273
43. Lonning PE, Geisler J (2008) Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. J Steroid Biochem Mol Biol 108(3-5):196-202. doi:10.1016/j.jsbmb.2007.09.017
44. Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjorn B, Dowsett M, Einstein Lonning P (2001) Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 7(5):1230-1236
45. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura A, Lawrence J Jr, Berstein L, Yue W (2005) Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 12(Suppl 1):S61-S73. doi:10.1677/erc.1.01018